Scinai Immunotherapeutics Files 2023 Annual Report

TL;DR

Scinai dropped its 2023 financials and 20-F. Check it out.

AI Summary

Scinai Immunotherapeutics Ltd. announced on May 6, 2024, the publication of its fiscal year 2023 financial statements and the filing of its Annual Report on Form 20-F. The company also provided a business update alongside these filings.

Why It Matters

This filing provides investors with the company's audited financial performance for 2023 and an update on its business operations, crucial for assessing its current standing and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing of annual financial statements and reports, not indicating new or significant risks.

Key Players & Entities

• Scinai Immunotherapeutics Ltd. (company) — Filer of the report
• May 6, 2024 (date) — Date of press release and announcement
• 2023 (date) — Fiscal year for financial statements
• Form 20-F (document) — Annual report filed by the company

FAQ

From the Filing

0001213900-24-043778.txt : 20240515 0001213900-24-043778.hdr.sgml : 20240515 20240515171007 ACCESSION NUMBER: 0001213900-24-043778 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240515 FILED AS OF DATE: 20240515 DATE AS OF CHANGE: 20240515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 24952476 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0206257-6k_scinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of May 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ On May 6, 2024, Scinai Immunotherapeutics Ltd. issued a press release announcing the publishing of FY 2023 financial statements and filing of Annual Report on Form 20-F and providing a business update. A copy of the press release is furnished herewith as Exhibit 99.1. This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344 ) and Form F-3 (File No. 333-274078 and File No. 333-276767 ), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibit Index Exhibit No. Description 99.1 Press Release, dated May 15, 2024 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: May 15, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2 EX-99.1 2 ea020625701ex99-1_scinai.htm PRESS RELEASE, DATED MAY 15, 2024 Exhibit 99.1 Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update JERUSALEM, ISRAEL – May 15, 2024 - Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI; “Scinai”, or the “Company”), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its full-year financial results for the year ended December 31, 2023, and provided a business update. Business Update & Recent Highlights Financing In support of the Company’s strategic pivot, on January 3, 2024, we raised $1.69 million in gross proceeds from the exercise of certain of our outstanding warrants and the issuance of new warrants. H.C. Wainwright & Co. acted as exclusive placement agent in connection with the offering. On November 6, 2023, we announced that the Israel Innovation Authority had approved a non-dilutive grant reimbursing us for 66% of the costs of a project valued at NIS 3.5 million supporting the establishment of a CDMO service business unit out of our cG